Patient Square Capital LP

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Patient Square Capital LP reported 2 stock positions worth $234.8 million. Its top holding was Roivant Sciences (ROIV) at 54.9% of the portfolio, followed by Liquidia (LQDA, 45.1%). Compared with Q4 2023, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Liquidia (LQDA) and the biggest sale Roivant Sciences (ROIV, shares −3%).

Most Recent 13F
Q2 2026
Location
MENLO PARK, CA
CIK
0001819257
Portfolio Value
$234.8M (Q1 2024)
SEC Filing
0000950123-24-005073 ↗ filed May 14, 2024

Holdings Value

0$200.0M$400.0M$600.0M$800.0M Q1 2024: $234.8M $234.8M Q1 2024 Q2 2024: $215.4M Q2 2024 Q3 2024: $269.4M Q3 2024 Q4 2024: $267.4M Q4 2024 Q1 2025: $241.7M Q1 2025 Q2 2025: $277.4M Q2 2025 Q3 2025: $373.9M Q3 2025 Q4 2025: $467.1M Q4 2025 Q1 2026: $563.6M Q1 2026 Q2 2026: $645.5M Q2 2026

Holdings 2 stocks · $234.8M
ROIV Roivant Sciences Ltd. 54.89% 12,228,465 $128.9M Reduce -3.3%
LQDA Liquidia Corp. 45.11% 7,182,532 $105.9M New

Portfolio Sells Q4 2023 → Q1 2024
ROIV Roivant Sciences Ltd. Reduce -3.3% 54.89% −22.71
EAR Eargo Inc. Sold out 0.00% −22.40

Portfolio Buys Q4 2023 → Q1 2024
LQDA Liquidia Corp. New 45.11% +45.11

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 23$645.5MROIV, RVMD, MIRM, ABVX, ONC
Q1 2026 29$563.6MROIV, ARGX, INSM, ONC, COGT
Q4 2025 28$467.1MROIV, INSM, MIRM, ARGX, ONC
Q3 2025 24$373.9MROIV, INSM, EYPT, ABVX, CDTX
Q2 2025 19$277.4MROIV, INSM, ARGX, EYPT, LQDA
Q1 2025 19$241.7MROIV, INSM, LQDA, EYPT, OCUL
Q4 2024 20$267.4MROIV, LQDA, INSM, CGEM, EYPT
Q3 2024 11$269.4MROIV, LQDA, CGEM, INSM, EYPT
Q2 2024 2$215.4MROIV, LQDA
Q1 2024 2$234.8MROIV, LQDA